CEO Executive AssistantAdmin Support for Healthcare CEO Women’s Health Program Coordination
Women’s health is one of the most strategically significant and operationally complex service lines in health system leadership. For healthcare CEOs leading women’s health programs, the scope extends from obstetrics and maternal-fetal medicine to gynecologic oncology, fertility services, and midwifery. Clinical quality metrics carry regulatory weight, community trust is hard-won and easily lost, and capital investment decisions involve long development timelines with significant reimbursement complexity.
Executive assistants who support healthcare CEOs in this environment must understand the operational anatomy of women’s health program leadership. This article outlines how high-performing EAs structure their support across service line reviews, maternal outcomes governance, board preparation, and program development milestone tracking.
Scheduling Women’s Health Service Line Reviews and OB/GYN Leadership Briefings
Building a Structured Review Calendar
Women’s health service line reviews require participation from a wide range of clinical and operational leaders: the chief of obstetrics, the director of women’s services, the CNO or women’s health nursing director, the CFO’s service line finance partner, and often the quality officer. The EA’s first responsibility is building a meeting cadence that keeps this group aligned without overwhelming clinical leaders who carry patient care obligations.
A well-designed review calendar typically includes a monthly operational performance review, a quarterly strategic review that incorporates volume trends and service line financial performance, and an annual planning session that feeds into the health system’s capital and operating budget cycles. The EA owns the scheduling logistics for each of these sessions: confirming room availability or video conferencing infrastructure, distributing agenda materials in advance, and ensuring the CEO has adequate preparation time before each meeting.
Pre-meeting briefing packages are a critical EA deliverable. For service line reviews, these packages should include volume data by service (deliveries, outpatient visits, surgical cases), quality scorecards covering NTSV cesarean rates and maternal complication indicators, patient satisfaction scores, and any flagged operational issues from the prior period. The EA works with the women’s services director and data analytics team to compile these materials and formats them to match the CEO’s preferred briefing style.
Coordinating OB/GYN Leadership Briefings
Beyond formal service line reviews, the CEO engages regularly with OB/GYN department chairs and clinical program directors on specific issues: new physician recruitment, clinical protocol updates, community outreach partnerships, and accreditation preparation. The EA schedules these briefings with attention to clinical schedules, avoiding OR block times and clinic hours that create hardship for physician leaders.
When a new OB/GYN chair or women’s services director is onboarding, the EA coordinates a structured introductory briefing sequence with the CEO, ensuring the new leader has direct access to the CEO’s strategic priorities for the service line. This early relationship investment pays dividends in alignment throughout the year.
Coordinating CEO Engagement with Maternal-Fetal Medicine and Midwifery Leadership
Supporting MFM Program Relationships
Maternal-fetal medicine represents the clinical flagship of a women’s health program. MFM physicians lead high-risk obstetric care, fetal diagnosis, and the clinical protocols that govern maternal outcomes across the service line. For healthcare CEOs, maintaining a productive working relationship with MFM leadership is essential to both quality performance and program development.
The EA coordinates the CEO’s engagement with MFM leadership across several touchpoints: quarterly program update briefings, grand rounds appearances, and joint sessions with the perinatal quality committee. When MFM leadership is presenting a new clinical protocol or a capital request for advanced ultrasound equipment, the EA ensures the CEO receives a background briefing before the formal presentation so the meeting is productive rather than introductory.
MFM programs also interface with academic medical centers through faculty appointments, research collaborations, and fellowship training. When these relationships involve CEO-level engagement, such as a joint program development discussion with a university department chair, the EA manages the scheduling, prepares the CEO’s briefing, and handles follow-up documentation.
Supporting Midwifery Program Leadership
Certified nurse-midwife programs have grown significantly within health systems as organizations respond to patient demand for lower-intervention birth options and work to improve NTSV cesarean rate performance. For CEOs leading health systems with active midwifery programs, maintaining direct engagement with CNM leadership signals institutional commitment and supports recruitment and retention.
The EA schedules the CEO’s periodic meetings with the director of midwifery services and ensures these sessions are substantive rather than ceremonial. Briefing materials should include midwifery delivery volume trends, CNM provider satisfaction data, and any active contract or scope-of-practice issues that require CEO attention. When midwifery leadership is presenting a program expansion proposal, the EA coordinates the review process across nursing, medical staff, and finance before the CEO meeting.
Managing Maternal Mortality and Morbidity Review Committee Logistics
Coordinating Sensitive Clinical Governance Meetings
Maternal mortality and morbidity review committees are among the most sensitive clinical governance structures in a health system. These committees review adverse maternal outcomes, identify system and process failures, and develop improvement recommendations. CEO engagement with these committees signals institutional commitment to maternal safety and is increasingly expected by accreditors and public health agencies.
The EA’s role in supporting these committees requires particular attention to confidentiality and document security. Meeting materials, case summaries, and committee deliberations are typically protected under state peer review statutes, and the EA must ensure that document distribution follows established legal and compliance protocols. This means using secure document management platforms, confirming that distribution lists are approved by legal counsel, and ensuring that materials are not forwarded outside the authorized committee membership.
Scheduling these meetings requires coordination with a cross-functional committee that may include the chief medical officer, chief nursing officer, department chairs, risk management, and patient safety leadership. The EA identifies a regular meeting cadence (typically monthly or bimonthly) and maintains that cadence through leadership transitions and calendar disruptions.
Supporting CEO Preparation for Committee Participation
When the CEO participates in maternal mortality review committee sessions, the EA prepares a concise briefing covering the cases on the agenda at a summary level, the committee’s current improvement priorities, and any regulatory or accreditation context relevant to the cases under review. This preparation allows the CEO to engage substantively without spending extended time reading full case documentation.
After committee meetings, the EA tracks action items assigned to the CEO or to teams that report to the CEO, and follows up on completion timelines. When the committee’s recommendations require capital investment or operational change, the EA coordinates the process of routing those recommendations through the appropriate governance channels.
Preparing Board Presentations on Women’s Health Volume and NTSV Cesarean Rate Performance
Building Board-Quality Women’s Health Reporting
Board reporting on women’s health programs must translate clinical performance into strategic and financial terms that resonate with trustees. The EA does not author board presentations, but the EA’s coordination of the materials assembly process determines whether those presentations are complete, accurate, and delivered on time.
Effective women’s health board presentations typically cover: total delivery volume and trend versus prior year and budget, outpatient women’s health visit volume by service category, NTSV cesarean rate performance against national benchmarks and Leapfrog standards, maternal complication rates and comparison to peer institutions, service line operating margin, and pipeline investments including new facility development or program launches.
The EA works with women’s services leadership, finance, and quality to collect each data element and tracks submission deadlines to ensure the CMO and CFO have adequate review time before materials go to the board. When data elements are late, the EA escalates to the appropriate department head rather than waiting for the deadline to pass.
Formatting consistency matters at the board level. The EA maintains presentation templates aligned with board governance standards and ensures that women’s health slides follow the same visual and data conventions used across other board materials. For healthcare CEOs who present to a quality committee or a patient experience committee in addition to the full board, the EA manages a tiered presentation calendar that coordinates materials across all bodies.
Framing NTSV Performance for Board Audiences
NTSV cesarean rate performance is a high-profile quality metric that receives attention from CMS, The Joint Commission, Leapfrog, and state health departments. When a health system’s NTSV rate is above benchmark, board members will ask pointed questions. The EA supports the CEO’s board preparation by scheduling a pre-board briefing with the CMO and women’s services director to review the data, understand improvement initiatives, and anticipate board questions.
This coordination function is described in more detail in the context of clinical operations coordination, which covers how EAs support CEOs across the full spectrum of clinical performance governance.
Tracking Level III NICU Development and Fertility Program Launch Milestones
Managing NICU Development Timelines
Level III NICU designation and development represents one of the most complex capital projects a women’s health program can undertake. The project involves facility construction or renovation, technology acquisition, physician and nursing recruitment, neonatology program development, and regulatory approval. For healthcare CEOs sponsoring this work, the ability to track progress against a detailed milestone plan is essential.
The EA maintains a NICU development milestone tracker that covers every major workstream: construction schedule milestones, neonatology recruitment targets and timelines, nursing FTE hiring and training plans, equipment procurement and installation, state health department licensing applications, and accreditation preparation. Each milestone is assigned an owner, a target date, and a status that the EA updates based on weekly check-ins with the project management team.
When milestones slip, the EA surfaces the delay to the CEO with a brief summary of the cause and the downstream impact on the overall project timeline. This early warning function gives the CEO the opportunity to intervene before a milestone delay cascades into a project-level problem.
The EA also schedules the CEO’s periodic construction site visits and stakeholder briefings, including community announcements and physician town halls that are part of the program development communications plan.
Coordinating Fertility Program Launch Logistics
Fertility program launches involve a distinct set of milestones: embryology laboratory buildout and CLIA certification, reproductive endocrinologist recruitment, reproductive urology and genetics partnerships, payer contracting for fertility services, and patient access infrastructure including scheduling and financial counseling. The EA tracks these milestones with the same rigor applied to NICU development, maintaining a running status report and flagging delays to the CEO.
Fertility programs also require close coordination with legal and compliance on advertising standards, patient financial disclosure requirements, and state-specific fertility law compliance. The EA schedules the CEO’s engagement with legal counsel on these issues and tracks the completion of required compliance reviews before launch.
McKinsey’s research on women’s health strategy highlights that health systems making coordinated investments in women’s health across the care continuum achieve stronger patient loyalty and superior market share performance. The EA’s coordination infrastructure is what makes that coordinated investment operationally coherent at the CEO level.
Supporting Quality Improvement Initiatives in Women’s Health
Connecting Quality Governance to CEO Oversight
Women’s health quality improvement encompasses clinical protocol development, staff education, technology implementation, and performance monitoring. For healthcare CEOs, staying connected to quality improvement progress without becoming a bottleneck requires a structured information flow that the EA designs and maintains.
The EA schedules quarterly briefings between the CEO and the women’s health quality improvement team, ensuring these sessions include both data review and forward-looking discussion of initiatives in progress. When a quality improvement project reaches a key milestone (a new protocol goes live, a target metric is achieved), the EA ensures the CEO receives a brief notification so the accomplishment can be acknowledged with the clinical team.
Quality improvement coordination in women’s health also connects to accreditation activities. The Joint Commission’s Perinatal Care certification and the Society for Maternal-Fetal Medicine’s Maternal Levels of Care designation both require ongoing documentation of quality activities. The EA tracks accreditation calendars and coordinates the CEO’s participation in required leadership reviews.
This quality governance work is covered in broader context in quality improvement coordination, which describes how EAs support healthcare CEOs across all quality and patient safety functions.
Conclusion
Healthcare CEOs leading women’s health programs are accountable for clinical quality, financial performance, program development, and community trust simultaneously. The operational complexity of this leadership role is substantial, and the consequences of coordination failures, whether a missed board presentation deadline, a stalled NICU development milestone, or a poorly prepared maternal outcomes committee meeting, are real.
Executive assistants who understand the women’s health landscape provide coordination support that goes well beyond calendar management. By building disciplined meeting structures for service line reviews and clinical governance, managing the logistics of sensitive maternal mortality committees, preparing board-quality reporting materials, and tracking complex program development milestones, EAs create the operational foundation that allows healthcare CEOs to lead their women’s health programs with authority and effectiveness.
For health systems where women’s health is a strategic priority, an EA who understands this environment is not overhead. The EA is a direct contributor to program quality and organizational performance.